A large analysis presented at Kidney Week and published in JAMA found that sodium‑glucose cotransporter‑2 (SGLT2) inhibitors provide kidney and heart protection across a broad range of glomerular filtration rates and albuminuria levels, including many non‑diabetic patients. The data consolidate evidence for routine use of SGLT2 inhibitors beyond traditional diabetic populations and across varying degrees of albuminuria. Investigators reported consistent reductions in kidney outcomes and hospitalizations for heart failure, supporting guideline expansion and payer coverage discussions. The findings could influence prescribing patterns and reimbursement decisions for a drug class increasingly positioned as foundational in nephrology and cardiorenal care.